

# Information Technology, Improved Access, and Use of Prescription Drugs

---

Petri Böckerman<sup>†</sup>, Mika Kortelainen<sup>††</sup>, Liisa T. Laine<sup>‡</sup>, Mikko Nurminen<sup>‡‡</sup>, Tanja Saxell<sup>‡‡‡</sup>

March 15, 2024

<sup>†</sup>University of Jyväskylä, Labour Institute for Economic Research, and IZA Institute of Labor Economics

<sup>††</sup>University of Turku, and Finnish Institute for Health and Welfare

<sup>‡</sup>University of Missouri

<sup>‡‡</sup>Social Insurance Institution of Finland

<sup>‡‡‡</sup>Aalto University, VATT Institute for Economic Research, and Helsinki GSE


## Access-overuse trade-off

- Ensuring access to health care is a central policy goal worldwide (WHO Human Rights 2022).
- Policy measures to improve access include lowering financial and non-financial barriers for receiving health care.
  - **Social benefits:** Mitigate unmet needs for care (Patel and Prince 2010).
  - **Social costs:** Expose some patients to overuse of medical services, resulting in fewer health benefits than harms (Brownlee et al. 2017).
- Improving access to health care without exposing patients to its overuse is a challenging but important trade-off to balance.

## This paper

- We study a large-scale public policy designed to improve access to medication while simultaneously limiting overuse.
- We analyze the adoption of a nationwide, fully interoperable electronic prescribing (e-prescribing) system that digitizes all prescriptions and their renewal requests in Finland.
  - **Improved medication access:** Digitization makes prescription renewal easier without an in-person physician visit.
  - **Comprehensive information on prescription history:** Can limit renewal of prescriptions for potentially overused or unnecessary medications, preventing downstream health harms.

# Empirical setting



E-prescribing Adoption Half-Year in Finnish Municipalities


- We analyze how the technology adoption balances the access-overuse trade-off for patients treated with benzodiazepines – highly effective but potentially addictive mental health and insomnia medications.
- We estimate the effects on benzodiazepine use and downstream health outcomes, using
  - A difference-in-differences (DiD) approach based on the staggered adoption of e-prescribing in Finnish municipalities.
  - Individual-level administrative data sets.

- We use nationwide administrative data sets for patients treated with benzodiazepines to analyze their prescription drug use, renewals, and downstream health outcomes at the intensive margin during 2007-2014.
  - Prescription data from the Social Insurance Institution of Finland.
  - Hospital discharge data from the Finnish Institute for Health and Welfare.
- We also combine the prescription data with the entire Finnish adult population from the Statistics Finland at the individual level to analyze first-time benzodiazepine use at the extensive margin in this population.

## Access barriers are greater among younger patients




(a) Daily doses of benzodiazepines



(b) Hospitalization for mental and behavioral disorder

- Access barriers to medication, as well as mental and behavioral disorders, are more common in the younger population (Kurko et al. 2015).

## Prescription drug abuse is concentrated among younger patients



Hospitalization for prescription drug abuse

- Hospitalizations for prescription drug abuse are strongly concentrated among younger patients, despite their lower level of benzodiazepine use.

## Econometric approach


We estimate DiD models using the two-way fixed effects (TWFE) specification:

$$y_{imt} = \rho \mathbb{1}[t - E_m \geq 0] + \alpha_i + \gamma_t + \epsilon_{imt},$$

- $y_{imt}$  is a benzodiazepine-related outcome for individual  $i$  in municipality  $m$  at time  $t$  (a period of six months),  $\mathbb{1}[t - E_m \geq 0]$  is the post-adoption indicator,  $E_m$  is the municipality's adoption date, and  $\alpha_i$  and  $\gamma_t$  are the individual and time fixed effects.
- $\rho$ : the intention-to-treat (ITT) effect of e-prescribing (due to voluntary take-up of the policy).
- We also estimate several other specifications that account for heterogeneous effects and address concerns related to potential pretrends and negative weights in TWFE.



# Take-up rate of e-prescriptions increased sharply after municipality adoption



Conditional Take-up Rate of E-prescriptions

- Approximately 50 percent of benzodiazepine prescriptions were issued electronically one year after the municipality's technology adoption.

## E-prescribing increased benzodiazepine use on average

- Our intention-to-treat (ITT) estimates show that the nationwide e-prescribing system has only little effect on the probability of initiating benzodiazepine treatment at the extensive margin.
- At the intensive margin, the total amount of benzodiazepine use per patient increases by 3% and there is also a 7% increase in long-term (more than 6-months) benzodiazepine use after e-prescribing.
- These increases at the intensive margin of benzodiazepine use result from increased prescription renewals, consistent with e-prescribing improving access to medication through easier renewal.

## Benzodiazepine use increased most among younger patients

- The quantitative magnitude of the increase in the total amount of benzodiazepine use is over twice as large for younger patients (aged 18–39) as for the elderly (age over 65).
- Long-term use increased by 12 percent among younger patients after e-prescribing.
  - Long-term benzodiazepine use should be, however, avoided according to clinical treatment guidelines due to the increased risks of physical dependence, addiction, and other health harms related to medication overuse.

## Health outcomes worsened for younger patients but improved for the elderly

- Hospitalizations for prescription drug abuse disorders and poisonings increased by approximately 10 percent among younger patients.
- No clear improvements in health outcomes (e.g., emergency department visits and mental health outcomes) among younger patients, despite their increased use of benzodiazepines.
- In contrast, for the elderly patients (age 65 over), e-prescribing reduces certain adverse drug effects, consistent with an improvement in information provision and success in balancing the access-overuse trade-off.

## Discussion

- Our results based on a nationwide staggered adoption of information technology and individual-level administrative data show e-prescribing improving access to medication.
- Improved access predominantly affected younger patients at higher risks of mental and behavioral disorders.
- Improved medication access due to easier renewal exposed some younger patients to medication overuse and related health harms.
- In contrast, e-prescribing benefited the health of the elderly patients by mitigating certain adverse drug effects among them.

- The ability of e-prescribing to balance the access-overuse trade-off depends on whether the improved access to medication offsets the benefits of improved information provision for physicians.
- Reducing the hassle costs associated with prescription renewal without additional monitoring for addiction in place may impair the targeting of high-risk medications.
  - Consistent with findings from research on ordeal mechanisms in social and welfare programs (e.g., Finkelstein and Notowidigdo 2019).
- Further research on other drug classes is needed to fully understand the effects of e-prescribing technology.

- Brownlee, S., K. Chalkidou, J. Doust, A. G. Elshaug, P. Glasziou, I. Heath, S. Nagpal, V. Saini, D. Srivastava, K. Chalmers, and D. Korestein (2017). Evidence for Overuse of Medical Services Around the World. *The Lancet* 390 (10090), 156–168.
- Finkelstein, A. and M. J. Notowidigdo (2019). Take-up and Targeting: Experimental Evidence from SNAP. *The Quarterly Journal of Economics* 134 (3), 1505–556.
- Hawks, L., D. U. Himmelstein, S. Woolhandler, D. H. Bor, A. Gaffney, and D. McCormick (2020). Trends in Unmet Need for Physician and Preventive Services in the United States, 1998-2017. *JAMA Internal Medicine* 180 (3), 439–448.
- Patel, V. and M. Prince (2010). Global Mental Health: A New Global Health Field Comes of Age. *JAMA* 303 (19), 1976–1977.